RXRX
Recursion Pharmaceuticals Inc
NASDAQ: RXRX · HEALTHCARE · BIOTECHNOLOGY
$3.46
+4.85% today
Updated 2026-04-30
Market cap
$1.80B
P/E ratio
—
P/S ratio
24.12x
EPS (TTM)
$-1.44
Dividend yield
—
52W range
$3 – $7
Volume
13.8M
Recursion Pharmaceuticals Inc (RXRX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-328.80%
ROE
-59.50%
ROA
-27.70%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $1.71M | $-62.52M | -2,577.32% | -3,649.39% | -3,654.30% |
| 2020 | $3.41M | $-87.01M | 100.00% | -2,479.20% | -2,549.25% |
| 2021 | $10.00M | $-178.07M | 100.00% | -1,827.75% | -1,780.74% |
| 2022 | $39.68M | $-239.42M | -21.66% | -619.26% | -603.36% |
| 2023 | $43.88M | $-328.07M | 2.94% | -797.84% | -747.71% |
| 2024 | $58.84M | $-463.66M | 23.12% | -814.09% | -788.02% |
| 2025 | $74.68M | $-644.76M | -61.96% | -867.87% | -863.35% |